← Back to Search

Behavioural Intervention

Pharmacy-Based STBBI Testing for HIV, Hepatitis C, and Syphilis

N/A

Recruiting

Research Sponsored by Memorial University of Newfoundland

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Ages 18 years and older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up collected at the end of the study period (approximately one year)

Awards & highlights

Study Summary

This trial will assess the impact of a pharmacy-based testing program for HIV, hepatitis C, and syphilis in participating pharmacies in three Canadian provinces.

Who is the study for?

The APPROACH 2.0 study is for English-speaking adults (18+) in Canada with a provincial health card who can consent to participate. It's not for those already diagnosed with HIV or HCV, but they may still get certain tests.Check my eligibility

What is being tested?

This trial offers pharmacy-based testing for HIV, hepatitis C, and syphilis using point of care tests or dry blood spot tests. The goal is to see if this approach helps find new cases and connect people to care.See study design

What are the potential side effects?

There are no direct side effects from participating as it involves non-invasive testing procedures. However, there might be emotional or psychological impacts due to the results of the STBBI tests.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ collected at the end of the study period (approximately one year)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~collected at the end of the study period (approximately one year)

This trial's timeline: 3 weeks for screening, Varies for treatment, and collected at the end of the study period (approximately one year) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Hepatitis C

HIV Infections

Number and proportion of new syphilis infections found through pharmacy testing in each province

Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants requesting test(s) for HIV, HCV, and/or syphilisExperimental Treatment1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial University of NewfoundlandLead Sponsor

68 Previous Clinical Trials

1,831,022 Total Patients Enrolled

Media Library

Choice of STBBI test(s) (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05534633 — N/A

Human Immunodeficiency Virus Infection Research Study Groups: Participants requesting test(s) for HIV, HCV, and/or syphilis

Human Immunodeficiency Virus Infection Clinical Trial 2023: Choice of STBBI test(s) Highlights & Side Effects. Trial Name: NCT05534633 — N/A

Choice of STBBI test(s) (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05534633 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies remaining for this study?

"Based on the information published at clinicaltrials.gov, recruitment for this medical experiment has been suspended and was last updated in September 6th 2022. At present, 1270 other trials are recruiting patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies

Deborah Kelly 2022. "APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05534633.